Etzer Darout: Great. Thanks for taking the question. First one, just wondered if you plan to disclose any of the data from the dose escalation of vobra duo plus lorigerlimab prior to moving into expansion studies? And then secondly, if you maybe could comment on the progress of any of the kind of other tumor types, Lori sort of monotherapy, maybe any progress there with other tumor types when we could get an update there or any other tumor types that you would look to explore with Lori or either monotherapy or combinations? Thank you.
Scott Koenig: Yes. So, Etzer, we’ll have to again, as you know, as I’ve said just earlier today, we’re honing in on the specific doses for the individual components of the vobra duo combo. Ultimately, it will be determined of how many patients we have available at that time to assess. My inclination right now is to start and move forward in expansions in particular types, which I alluded to before, prostate and probably one or two others. And probably at that time, once we have that data, we would be in, I think, a better position to present the total data but again, this is subject to further discussions later this year. With regard to other tumor types of Lori besides the data we presented at ASCO GU, as you know, we have previously said that we’ve had objective responses in three other cohorts that we were testing, including MS stable colorectal cancer melanoma and lung cancer.
What I’ve also indicated on previous calls is that for us to move forward into a more wholesome Phase 2 study, I’d like to see some additional patients being treated as monotherapy to get — to better determine the activity in particular tumors. I pointed out, for example, in the lung cancer cohort that we had, we lost a lot of that data because of patients that were treated in Ukraine for the case of the stable colorectal cancer patients. I pointed out we had very few patients without liver metastasis, which has being pursued by others, so I’d like to see additional patients being treated as monotherapy before making the decisions going forward. The melanoma data, we’re very encouraged by. As you know, historically, we’ve had we have noted that we’ve had very significant responses in with vobra duo and melanoma as well.
And that is one of the tumor types where potentially enrolling in the combination study going forward.
Etzer Darout: Great. Thank you.
Operator: Thank you. Our next question comes from Kaveri Pohlman with BTIG. Your line is open.
Kaveri Pohlman: Yes, good evening. Thank you. Thanks for the update and for taking my questions. Sorry if I missed this, but for lorigerlimab and docetaxel combination study, it’s a randomized trial for 150 patients, can you give us a sense on how long it will take to enroll the study and to get RPFS? Also, do you think that you can just expand it to a free trial if the interim data looks good. Just want to know how you’re thinking about it?
Scott Koenig: Yes, Kaveri, thank you very much. So, we’re very close to enrolling the first patients. We’ve initiated sites. Patients are being screened now. So, we’re really on target for what we have said with regard to the start-up of this trial. Right now, until you start enrolling, you won’t know the rate of enrollment. But right now, the anticipation will take us through this year and through a good part of 2024. And so at this point, it would be just too early to predict when we’d be able to do the readout at the study, most likely in early 2025, but that’s all conjecture at this point.
Kaveri Pohlman: Got it. That’s very helpful. And then for MGD-024, can you tell us how is the enrollment going? Any feedback you have received from the physicians so far? And can you accelerate dosing based on your previous clinical experience with lorigerlimab here?
